Literature DB >> 19495942

Delivered dose: a drug-centric phenotype for chemotherapy dose individualization.

Y Bruce Yu1.   

Abstract

It is pointed out that genotype-based approaches are unlikely to be effective at dose individualization. Delivered dose, which refers to the amount of drug delivered to the point of action to be measured by quantitative imaging techniques, is a drug-centric phenotype that separates pharmacokinetic effects from pharmacodynamic effects. Delivered dose serves as a midway measurable numeric parameter between drug administration and therapy outcome. One potential way to reduce chemotherapy outcome variation is to individualize prescribed drug so that uniform delivered dose is achieved across the patient population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495942     DOI: 10.1007/s11095-009-9913-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  "Getting the dose right": facts, a blueprint, and encouragements.

Authors:  C C Peck; J T Cross
Journal:  Clin Pharmacol Ther       Date:  2007-07       Impact factor: 6.875

Review 2.  The utility of microdosing over the past 5 years.

Authors:  Graham Lappin; R Colin Garner
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

Review 3.  Local kinetics and dynamics of xenobiotics.

Authors:  Olavi Pelkonen; Jaime Kapitulnik; Ursula Gundert-Remy; Alan R Boobis; Armel Stockis
Journal:  Crit Rev Toxicol       Date:  2008       Impact factor: 5.635

4.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Authors:  Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

5.  Drug distribution. The forgotten relative in clinical pharmacokinetics.

Authors:  H G Eichler; M Müller
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 6.  Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.

Authors:  Jiunn H Lin
Journal:  Curr Drug Metab       Date:  2007-02       Impact factor: 3.731

Review 7.  Somatic pharmacogenomics in cancer.

Authors:  O N Ikediobi
Journal:  Pharmacogenomics J       Date:  2008-08-05       Impact factor: 3.550

Review 8.  Biomarkers in early cancer drug development: limited utility.

Authors:  R H Glassman; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-02       Impact factor: 6.875

9.  How to calculate the dose of chemotherapy.

Authors:  Howard Gurney
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

Review 10.  Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.

Authors:  R O Dillman
Journal:  Clin Exp Med       Date:  2006-03       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.